Nuria Pares-Herbute

HPLC detection of dopamine and noradrenaline in the cochlea of adult and developing rats

The presence and postnatal development of dopamine (DA) and noradrenaline (NA) in the rat cochlea were detected by high-performance liquid chromatography coupled with electrochemical detection. Cochlear DA content rose gradually after birth. Conversely, NA concentrations rose rapidly between postnatal day 1 and 8; then, up to day 30, it increased more slowly. On day 30, both DA and NA levels were around 5 times higher than on day 1. In the adult rat cochlea, NA mean content was 234 +/- 22.2 pg/mg protein, while DA mean content was 23.6 +/- 1.1 pg/mg protein. Adrenaline was always undetectable. The present study is the first report describing directly the presence of DA in the rat cochlea. DA might serve as one of the lateral efferent neurotransmitters, whereas NA probably acts as a neurotransmitter of the sympathetic cochlear innervation. Nevertheless, their influences on the cochlear physiology, either in adulthood or during development are still a matter of discussion.

Ontogeny of the metencephalic, mesencephalic and diencephalic content of catecholamines as measured by high performance liquid chromatography with electrochemical detection

Developmental changes in norepinephrine (NE), dopamine (DA) and epinephrine (E) contents of the rat metencephalon, mesencephalon and diencephalon, have been measured by high performance liquid chromatography with electrochemical detection, from fetal stages (E15 or E17 to E21) to postnatal days (P0 to P30) and compared to the adult levels. The data show a biphasic pattern in NE changes of the three brain areas, with a first increase in the late prenatal period, followed by a further development from PO to P18, thus reaching the adult levels. A similar pattern of development is found for the mesencephalic and diencephalic DA contents. The E levels of the diencephalon are very low in comparison to the NE and DA concentrations, but present a gradual increase from E17 to P18. The results correlate with the development of catecholamine systems in brain area as measured by other methodological approaches.

Adenylate cyclase activation is not sufficient to stimulate somatostatin release from dispersed cerebral cortical and diencephalic cells in glia-free cultures.

Under conditions in which vasoactive intestinal peptide (VIP) induces somatostatin release from cortical and diencephalic neuronal cultures, VIP causes large increases in intracellular cyclic AMP. Both the release of somatostatin and the increase in cyclic AMP elicited by VIP require exogenous calcium, can be blocked by cobalt ion, and can be qualitatively mimicked by depolarizating concentrations of exogenous potassium ion. Direct activation of adenylate cyclase by forskolin causes large increases in cyclic AMP content but does not induce somatostatin release. In the absence of VIP, the calcium ionophore, ionomycin, and the phorbol ester, phorbol 12-myristate-13-acetate, also stimulate somatostatin release. These results indicate that VIP-stimulation of cyclic AMP formation and VIP-stimulation of somatostatin release are calcium-dependent and that the two phenomena are dissociatable. Cyclic AMP formation is not a necessary condition for VIP-induced somatostatin release. Nucleotide formation may be a sufficient condition for release or, possibly in association with calcium influx, it may be an event unrelated to the release process.

The presence of non-neuronal cells influences somatostatin release from cultured cerebral cortical cells

We examined the effect of non-neuronal cells on somatostatin release from cultured cerebral cortical cells. Three culture models were used: (1) neuron-enriched cultures obtained from cortex of 17-day-old rat embryos and exposed to 10 microM cytosine arabinoside (Ara C) for 48 h between days 3 and 5 after plating; (2) whole cell cultures obtained by using the same protocol but untreated with Ara C; (3) glial primary cultures obtained from newborn rats. We studied: (i) the cellular composition of the cultures by using two astroglial markers: vimentin and glial fibrillary acidic protein (GFAP); (ii) the spontaneous and forskolin-stimulated somatostatin release. In 8-day-old cultures morphological data revealed that Ara C treatment reduced glial cells to 6%. At 7 and 10 days of culture somatostatin spontaneously released from Ara C-treated cells was higher than that measured from untreated cells. On the 17th day of culture, neuron-enriched cultures contained a lower amount of somatostatin than whole cell cultures. Forskolin elicited a dose-dependent release of somatostatin from whole cell cultures, but had no effect on neuron-enriched cultures. Astroglial released media (ARM) from glial primary cultures exposed to forskolin for 20 min induced somatostatin release from neuron-enriched cultures. HPLC analysis of endogenous amino acids of ARM showed that glutamate, glutamine, glycine and alanine were significantly increased after forskolin stimulation. Our results suggest a functional interaction between glial cells and neurons secreting somatostatin.

Enhanced antiproliferative effect of nitric oxide in cultured smooth muscle cells from diabetic rats.

We examined the influence of experimental diabetes on the proliferation of cultured vascular smooth muscle cells (VSMCs) in presence of a nitric oxide (NO)-generating agent, sodium nitroprusside (SNP), and 8-bromo-cGMP. VSMC cultures were prepared from aortas of control and streptozotocin-diabetic rats. SNP induced a time- and dose-dependent inhibition of control and diabetic VSMC proliferation, consistent with the data on [3H]thymidine incorporation, cell counts, and index of culture mass. However, the responses to SNP were significantly enhanced in VSMCs from diabetic rats. SNP induced an increased dose-dependent accumulation of intracellular cGMP in diabetic VSMCs. In contrast, growth-inhibitory responses to 8-bromo-cGMP were not significantly different between the two VSMC models. Moreover, basal cGMP content in VSMCs was lower in diabetic rats than in controls, a result that can explain the enhanced proliferation observed in VSMCs from diabetic rats. These results suggest an enhanced antiproliferative effect of NO in VSMCs from diabetic rats through increased cGMP production. Therefore, experimental diabetes may impair and up-regulate soluble guanylate cyclase activity in VSMCs.

Calcium Dependence of Somatostatin (SRIF) Release and Cyclic AMP Levels in Cultured Diencephalic Neurons

Calmodulin has been reported to be involved in the Ca2+-dependent hypothalamus in vitro. The present experiments were undertaken to determine whether at an early stage of development (in diencephalic primary cultures secreting SRIF, on the 11th day) the activation of a Ca2+-calmodulin kinase system is also involved in the release of the peptide. Since a calmodulin-dependent adenylate cyclase activity has been detected in the brain, we measured intracellular cyclic AMP accumulation as an additional parameter of calmodulin activity. SRIF release and cyclic AMP accumulation were stimulated by K+ (56 mM) and by the Ca2+ ionophores ionomycin (0.5 microM) and A 23187 (in a dose-dependent manner). Incubation of cells in Ca2+-free Locke medium or in the presence of Co2+ (1 mM) completely blocked ionophore-induced SRIF release and cyclic AMP accumulation. Three calmodulin antagonists (calmidazolium, W-7, and chlorpromazine) and two blockers of calmodulin-dependent kinase (phenytoin and diazepam) were tested on evoked-SRIF release and cyclic AMP formation. Neither W-7 nor calmidazolium modified A 23187-induced SRIF release at any dose tested, although they inhibited, in a dose-dependent manner, the stimulatory effect of the Ca2+ ionophore on cyclic AMP accumulation.(ABSTRACT TRUNCATED AT 250 WORDS)

Involvement of nitric oxide in the inhibition of aortic smooth muscle cell proliferation by calcium dobesilate

Vascular smooth muscle cell (SMC) proliferation is a key process in the pathogenesis of atherosclerosis. Numerous factors are involved in the regulation of SMC growth. Nitric oxide (NO) induces the inhibition of SMC proliferation whereas oxidized low-density lipoproteins (LDL) have a mitogenic effect. Calcium dobesilate (Doxium) is an angioprotective agent for treating vascular diseases. It has been shown to increase NO production and to have antioxidant properties but its mechanism of action is not yet fully understood. This study investigated the effect of calcium dobesilate on proliferation of rat aortic SMC in culture. Proliferation was evaluated by cell number and DNA synthesis. Orally administered calcium dobesilate (30, 100, or 200 mg/kg/day for 7 days) induced a dose-dependent decrease of proliferation of SMC in primary culture compared with controls.In vitro treatment with calcium dobesilate (0.05–5 mM) inhibited both DNA synthesis and proliferation in a time- and concentration-dependent manner. In bothex vivo andin vitro models, the inhibition was reversible upon removal of the drug. Calcium dobesilate also stimulated NO production and NO synthase activity. Inhibitors of NO synthesis attenuated the inhibitory effect of calcium dobesilate (300 µM) on DNA synthesis. In addition, calcium dobesilate (2.5–40 µM) induced a dose-dependent protection of cooper-induced LDL oxidation. These results showed that calcium dobesilate inhibits SMC proliferation, partly by a NO-dependent mechanism, and suggest that it could be effective in the treatment of pathological disorders associated with vascular SMC proliferation.

Determination of protein-bound urinary gamma-carboxyglutamic acid in calcium nephrolithiasis

Nephrocalcin is a urinary gamma-carboxyglutamic acid (Gla) containing protein that may be a physiological inhibitor of calcium oxalate nephrolithiasis. Nephrocalcin isolated from urine of stone formers seems to be abnormal in lacking Gla that is required for inhibitory activity. In order to study this hypothesis, we compared the protein-bound urinary Gla contents in 32 calcium oxalate stone formers and in 24 controls. Protein-bound Gla was resolved by reversed-phase high-performance liquid chromatography after elimination of free Gla, alkaline hydrolysis and precolumn derivatization with o-phthalaldehyde and mercaptoethanol. Protein-bound urinary Gla concentrations were similar in stone formers (0.83 +/- 0.38 mumol/l, mean +/- SD) and controls (0.81 +/- 0.27) and were less than 5% of free urinary Gla. However, excretion rates of free and protein-bound Gla (nmol/min) were higher in stone formers (P = 0.006 and P = 0.002). Positive correlations (P = 0.000) were observed between free and protein-bound Gla both in controls and in stone formers. These results do not support the hypothesis of a lacking Gla nephrocalcin in stone formers.

Somatostatin inhibition of VIP-induced somatostatin release, cyclic AMP accumulation and 45Ca2+ uptake in diencephalic cells

The effect of somatostatin (SRIF) on VIP induction of SRIF secretion, cyclic AMP accumulation and 45Ca2+ influx was investigated in cultured diencephalic cells. [D-Trp8]SRIF suppressed VIP-stimulated SRIF release and decreased VIP-stimulated cyclic AMP accumulation in a dose-dependent manner. SRIF-14 blocked basal and VIP-stimulated 45Ca2+ entry into cells. The data suggest that the inhibitory effect of SRIF on VIP-induced SRIF release is partly due to a decrease in Ca2+ entry into cells.

Regulation of growth of cultured smooth muscle cells from diabetic rats by interleukin-1β: role of nitric oxide

We examined the influence of streptozotocin-induced diabetes on the growth of cultured rat aortic smooth muscle cells in the presence of interleukin-1 beta. Interleukin-1 beta induced a dose-dependent biphasic effect on proliferation of diabetic and control smooth muscle cells, consistent with the data on [3H]thymidine incorporation and cell counts. However, the major effect of interleukin-1 beta was to stimulate growth of diabetic cells and inhibit growth of control cells. Furthermore, interleukin-1 beta induced a dose-dependent increase in nitric oxide (NO) release and in intracellular cyclic GMP accumulation: nitrite release was similar in both smooth muscle cell models but cyclic GMP accumulation was greater in diabetic cells than in controls. These results suggest that the inhibitory loop involving NO is not effective enough to completely counterbalance the stimulatory effects of interleukin-1 beta on diabetic cells. Therefore, experimental diabetes may modify the interleukin-1 beta-regulated smooth muscle cell growth.